Large family sizes and crowded living conditions may play a role in transmission.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
Meanwhile, in cholera developments, the Africa CDC reports sharp rises in illnesses in Chad and the Republic of Congo.
Emergent BioSolutions has received a $56 million contract extension to supply the US government with doses of the ACAM2000 vaccine.
Meanwhile, Africa CDC extends its continental emergency declaration based on fragile progress, concerns about deaths, and the need to mobilize more resources.
Meanwhile, the US authorized the transfer of 219,000 vaccine doses, and the DR Congo deployed vaccine doses from Japan.
Cases and deaths have already outpaced totals for 2024, and new outbreaks have emerged in Gambia, Cameroon, and Mozambique.
The initiative is designed to accelerate testing, sequencing, capacity building, and local manufacturing for mpox and other priority pathogens.
Health officials facing depleted vaccine supplies are also tracking upticks in Nigeria, Liberia, Kenya, and Ghana, as well as in Togo and Mozambique.
WHO experts are seeing the same chikungunya warning signs that occurred two decades ago, when the virus swept across Indian Ocean countries.
The cases were reported in northern Mozambique near the Tanzanian border.
Despite declines in 2 high-burden countries, cases are rising in Burundi, Uganda, Ghana, Kenya, Liberia, and Guinea.
